# Evaluation of Oncoxin-Viusid® in Head and Neck Cancer

> **NCT03541772** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 60 (actual)

## Conditions studied

- Head Cancer Neck

## Interventions

- **DIETARY_SUPPLEMENT:** Oncoxin-Viusid®
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT03541772
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-20
- **Primary completion:** 2017-10-16
- **Final completion:** 2017-10-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03541772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03541772, "Evaluation of Oncoxin-Viusid® in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03541772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*